Engerix-B may be given subcutaneously to persons at risk of hemorrhage (eg, hemophiliacs). However, hepatitis B vaccines given subcutaneously are known to result in a lower antibody response.

Trials with Heplisav were halted last month in response to a serious adverse effect report from a phase 3 trial comparing Heplisav to a marketed hepatitis B vaccine, Engerix-B, sold by ...

Cumulative exposure for 7 days Manufacturer Hepatitis B vaccine (recombinant) Engerix-B (GlaxoSmithKline) 72 hr Manufacturer Immune globulin (human) Gamastan S/D (Bayer) Cumulative exposure for 7 ...